Table 2.
Comparison of patients with low PRFS and patients with high PRFS
| Variables | Low PRFS n = 31 |
High PRFS n = 25 |
p Value |
|---|---|---|---|
| Age (years), median (IQR 25–75) | 75 (69–80) | 81 (76–85) | 0.0094* |
| Male | 16 (51.6) | 22 (88.0) | 0.0037* |
| BMI (kg/m2), median (IQR 25–75) | 21.9 (20.8–24.0) | 23.1 (20.9–25.2) | 0.2839 |
| History of pT < 2 bladder cancer | 5 (13.5) | 4 (21.1) | 0.4703 |
| Left | 10 (32.3) | 18 (72.0) | 0.0066* |
| cT ≥ 3 | 5 (16.1) | 7 (28.0) | 0.3376 |
| Positive urine cytology | 12(38.7) | 9 (36.0) | 1.0000 |
| Multiple tumors | 1 (3.2) | 7 (28.0) | 0.0168* |
| Tumor size ≥ 3 cm | 8 (25.8) | 10 (40.0) | 0.3884 |
| pT ≥ 3 | 7 (22.6) | 10 (40.0) | 0.2425 |
| Cancer grade 3 | 24 (77.4) | 16 (64.0) | 0.3739 |
| LVI ( +) | 8 (25.8) | 4 (16.0) | 0.5163 |
| INF b, c | 21 (67.7) | 19 (76.0) | 0.5625 |
| Surgical margin ( +) | 2 (6.5) | 0 (0.0) | 0.4968 |
| ASC | 4 (12.9) | 4 (16.0) | 0.7426 |
| Local recurrence | 1 (3.2) | 0 (0) | 1.0000 |
| Distant metastasis | 3 (9.7) | 7 (28.0) | 0.0921 |
PRFS perirenal fat stranding, IQR interquartile range, BMI body mass index, LVI lymphovascular invasion, INF infiltrative growth, ASC adjuvant systemic chemotherapy
*p < 0.05